Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains

Ilija N. Cvijetić^{1*}, Tatjana Ž. Verbić², Pedro Ernesto de Resende³, Paul Stapleton³, Simon Gibbons³, Ivan O. Juranić⁴, Branko J. Drakulić^{4†}, Mire Zloh^{5*}

¹Innovation center of the Faculty of Chemistry, University of Belgrade, Studentski trg 16, Belgrade, Serbia

²Faculty of Chemistry, University of Belgrade, Studentski trg 16, Belgrade, Serbia

³UCL School of Pharmacy, University College London, London, UK

⁴Institute of Chemistry, Technology and Metallurgy, Department of Chemistry, University of Belgrade,

Njegoševa 12, Belgrade, Serbia

⁵University of Hertfordshire, College Lane, Hatfield, AL10 9AB, UK

*Corresponding authors: zloh@live.co.uk and ilija@chem.bg.ac.rs

[†] Authors regret to inform that Branko Drakulić has passed away since completion of the research for this paper.

NMR spectra



Figure S1. 1D ¹H and 1D ¹³C NMR spectra of (Z)-2-hydroxy-4-oxo-4-(o-tolyl)but-2-enoic acid (2).





Figure S2. 1D ¹H and 1D ¹³C NMR spectra of (Z)-2-hydroxy-4-oxo-4-(m-tolyl)but-2-enoic acid (3).

Figure S3. 1D ¹H and 1D ¹³C NMR spectra of (Z)-4-(4-butylphenyl)-2-hydroxy-4-oxobut-2-enoic acid (4).



Figure S4. 1D ¹H and 1D ¹³C NMR spectra of (*Z*)-4-(2,4-dimethylphenyl)-2-hydroxy-4-oxobut-2-enoic acid (5).



Figure S5. 1D ¹H and 1D ¹³C NMR spectra of (*Z*)-2-hydroxy-4-oxo-4-(2,4,5-trimethylphenyl)but-2-enoic acid (6).



Figure S6. 1D ¹H and 1D ¹³C NMR spectra of (Z)-2-hydroxy-4-oxo-4-(2,3,5,6-tetramethylphenyl)but-2-enoic acid (7).



Figure S7. 1D ¹H and 1D ¹³C NMR spectra of (*Z*)-2-hydroxy-4-oxo-4-(5,6,7,8-tetrahydronaphthalen-2-yl)but-2-enoic acid (8).



Figure S8. 1D ¹H and 1D ¹³C NMR spectra of 1-(4-ethyl-2,6-diisopropylphenyl)ethanone (5a).



Figure S9. 1D ¹H and 1D ¹³C NMR spectra of (*Z*)-2-hydroxy-4-oxo-4-(2,4,6-triisopropylphenyl)but-2-enoic acid (9).



Figure S10. 1D ¹H and 1D ¹³C NMR spectra of 4-oxo-4-(2,4,6-triisopropylphenyl)butanoic acid (2a).



Figure S11. 1D ¹H and 1D ¹³C NMR spectra of 4-([1,1'-biphenyl]-4-yl)-4-oxobutanoic acid (3a).



Figure S12. 1D ¹H and 1D ¹³C NMR spectra of (*Z*)-2-hydroxy-4-(4-methoxy-2,5-dimethylphenyl)-4-oxobut-2-enoic acid (**10**).



Figure S13. 1D ¹H NMR spectrum of (*Z*)-2-hydroxy-4-(4-hydroxy-3,5-dimethylphenyl)-4-oxobut-2-enoic acid (**11**).



Figure S14. 1D ¹H spectrum of 1-(2,5-dicyclohexylphenyl)ethanone (4a).



Figure S15. 1D ¹H and 1D ¹³C NMR spectra of (*Z*)-4-(2,5-dicyclohexylphenyl)-2-hydroxy-4-oxobut-2-enoic acid (**12**).



Figure S16. 1D ¹H NMR spectrum of 4-(2,5-dicyclohexylphenyl)-4-oxobutanoic acid (1a).



Figure S17. 1D ¹H and 1D ¹³C NMR spectra of (*Z*)-2-hydroxy-4-(2-methoxyphenyl)-4-oxobut-2-enoic acid (13).



Figure S18. 1D ¹H and 1D ¹³C NMR spectra of (*Z*)-2-hydroxy-4-(3-methoxyphenyl)-4-oxobut-2-enoic acid (14).



Figure S19. 1D ¹H and 1D ¹³C NMR spectra of (Z)-4-(3-bromophenyl)-2-hydroxy-4-oxobut-2-enoic acid (15).



Figure S20. 1D ¹H and 1D ¹³C NMR spectra of (*Z*)-2-hydroxy-4-oxo-4-(3-(trifluoromethyl)phenyl)but-2-enoic acid (**16**).



Figure S21. 1D ¹H and 1D ¹³C NMR spectra of (*Z*)-2-hydroxy-4-oxo-4-(4-(pyrrolidin-1-yl)phenyl)but-2-enoic acid (**17**).



Figure S22. 1D ¹H and 1D ¹³C NMR spectra of (*Z*)-2-hydroxy-4-(4-morpholinophenyl)-4-oxobut-2-enoic acid (**18**).



8.16 8.12 7.99 -7.10

7.58 7.53 7.27

Figure S23. 1D ¹H and 1D ¹³C NMR spectra of (Z)-4-(4-(1H-imidazol-1-yl)phenyl)-2-hydroxy-4-oxobut-2-enoic acid (19).



Figure S24. 1D ¹H and 1D ¹³C NMR spectra of (*Z*)-2-hydroxy-4-(4-(4-methylpiperazin-1-yl)phenyl)-4-oxobut-2-enoic acid (**20**).



Figure S25. 1D ¹H and 1D ¹³C NMR spectra of (*Z*)-4-(4-(dimethylamino)phenyl)-2-hydroxy-4-oxobut-2enoic acid (**21**).



Figure S26. Changes in fluorescence emission spectra of HSA ($c = 0.5 \,\mu\text{M}$) upon addition of comp. **12** ($c_{12} = 0.0; 0.25; 0.5; 0.75; 1; 1.5; 2.0; 3.0; 4.0 \,\mu\text{M}$); T = 293 K, left; T = 313 K, right; 30 mM PBS, pH = 7.38.